Difference between revisions of "Research/key-initiatives/ras/outreach/collaborations"
Jump to navigation
Jump to search
(Created page with "== RAS Collaborations == === Community Collaborations === The combined expertise of RAS Initiative researchers and the following outside organizations have expanded research...") |
(Marked this version for translation) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
| − | == RAS Collaborations == | + | <languages/> |
| + | <translate> | ||
| + | == RAS Collaborations == <!--T:1--> | ||
| − | === Community Collaborations === | + | === Community Collaborations === <!--T:2--> |
| + | <!--T:3--> | ||
The combined expertise of RAS Initiative researchers and the following outside organizations have expanded research capabilities and resulted in synergistic efforts to drive discoveries. | The combined expertise of RAS Initiative researchers and the following outside organizations have expanded research capabilities and resulted in synergistic efforts to drive discoveries. | ||
| − | === Pancreatic Cancer Action Network === | + | === Pancreatic Cancer Action Network === <!--T:4--> |
| + | <!--T:5--> | ||
Of all the cancers, pancreatic cancer is the one most often driven by mutations in RAS genes. The Pancreatic Cancer Action NetworkExit Disclaimer (PanCan) advocates for patients and raises funds for research. PanCan has coordinated with the RAS Initiative to fund postdoctoral awards and fellowships that complement the Initiative's work at the Frederick National Laboratory. | Of all the cancers, pancreatic cancer is the one most often driven by mutations in RAS genes. The Pancreatic Cancer Action NetworkExit Disclaimer (PanCan) advocates for patients and raises funds for research. PanCan has coordinated with the RAS Initiative to fund postdoctoral awards and fellowships that complement the Initiative's work at the Frederick National Laboratory. | ||
| − | === DARPA Big Mechanism Program === | + | === DARPA Big Mechanism Program === <!--T:6--> |
| + | <!--T:7--> | ||
The Defense Advanced Research Projects Agency (DARPA) has established the Big MechanismExit Disclaimer program to use machine learning to read abstracts and papers from the scientific literature to develop causal, explanatory relationships. The RAS Initiative is cooperating with the Big Mechanism Program to try to understand and reveal new ways to look at the RAS signaling network. | The Defense Advanced Research Projects Agency (DARPA) has established the Big MechanismExit Disclaimer program to use machine learning to read abstracts and papers from the scientific literature to develop causal, explanatory relationships. The RAS Initiative is cooperating with the Big Mechanism Program to try to understand and reveal new ways to look at the RAS signaling network. | ||
| − | === Department of Energy Pilot Program === | + | === Department of Energy Pilot Program === <!--T:8--> |
| + | <!--T:9--> | ||
The Department of Energy (DOE) maintains vast computational power as part of its own national missions. The DOE’s Molecular Level Pilot Program and the RAS Initiative are cooperating to apply the DOE’s unique capabilities to better model and understand how individual RAS molecules behave at the membrane in living cells. | The Department of Energy (DOE) maintains vast computational power as part of its own national missions. The DOE’s Molecular Level Pilot Program and the RAS Initiative are cooperating to apply the DOE’s unique capabilities to better model and understand how individual RAS molecules behave at the membrane in living cells. | ||
| − | === Technical Collaborations === | + | === Technical Collaborations === <!--T:10--> |
| + | <!--T:11--> | ||
Decades of effort by thousands of researchers around the world have resulted in numerous specialized tools and areas of knowledge that can be applied to better understand how cancers work. Scientists in the RAS Initiative have established cooperative relationships with outside experts to access the capabilities that are most important to attack mutant RAS. | Decades of effort by thousands of researchers around the world have resulted in numerous specialized tools and areas of knowledge that can be applied to better understand how cancers work. Scientists in the RAS Initiative have established cooperative relationships with outside experts to access the capabilities that are most important to attack mutant RAS. | ||
| + | <!--T:12--> | ||
*Mariano Barbacid, Spanish National Cancer Research Center | *Mariano Barbacid, Spanish National Cancer Research Center | ||
| + | <!--T:13--> | ||
*Cyril Benes, Massachusetts General Hospital | *Cyril Benes, Massachusetts General Hospital | ||
| + | <!--T:14--> | ||
*Marco Biancucci, Northwestern University - Chicago | *Marco Biancucci, Northwestern University - Chicago | ||
| + | <!--T:15--> | ||
*Larry Botticelli, Pharma Arava, LLC | *Larry Botticelli, Pharma Arava, LLC | ||
| + | <!--T:16--> | ||
*Arul Chinnaiyan, University of Michigan | *Arul Chinnaiyan, University of Michigan | ||
| + | <!--T:17--> | ||
*Geoffrey Clark, University of Louisville | *Geoffrey Clark, University of Louisville | ||
| + | <!--T:18--> | ||
*Channing Der, University of North Carolina | *Channing Der, University of North Carolina | ||
| + | <!--T:19--> | ||
*Martin Drysdale, Beatson Institute | *Martin Drysdale, Beatson Institute | ||
| + | <!--T:20--> | ||
*Walter Englaro, Sanofi-Aventis | *Walter Englaro, Sanofi-Aventis | ||
| + | <!--T:21--> | ||
*Sandra Gabelli, Johns Hopkins | *Sandra Gabelli, Johns Hopkins | ||
| + | <!--T:22--> | ||
*Angel Garcia, Los Alamos National Lab | *Angel Garcia, Los Alamos National Lab | ||
| + | <!--T:23--> | ||
*William Garland, Tosk, Inc. | *William Garland, Tosk, Inc. | ||
| + | <!--T:24--> | ||
*Rodolfo Ghirlando, NIDDK | *Rodolfo Ghirlando, NIDDK | ||
| + | <!--T:25--> | ||
*Michael Gross, Washington University | *Michael Gross, Washington University | ||
| + | <!--T:26--> | ||
*Jay Groves, University of California - Berkeley | *Jay Groves, University of California - Berkeley | ||
| + | <!--T:27--> | ||
*Frank Heinrich, National Institute for Standards and Technology | *Frank Heinrich, National Institute for Standards and Technology | ||
| + | <!--T:28--> | ||
*Paul Henderson, University of California - Davis | *Paul Henderson, University of California - Davis | ||
| + | <!--T:29--> | ||
*John Hunter, University of Texas - Southwestern | *John Hunter, University of Texas - Southwestern | ||
| + | <!--T:30--> | ||
*Esmaiel Jabbari, University of South Carolina | *Esmaiel Jabbari, University of South Carolina | ||
| + | <!--T:31--> | ||
*Hans Robert Kalbitzer, University of Regensburg - Germany | *Hans Robert Kalbitzer, University of Regensburg - Germany | ||
| + | <!--T:32--> | ||
*Perry Kennedy, H. Lee Moffitt Cancer Center & Research Institute | *Perry Kennedy, H. Lee Moffitt Cancer Center & Research Institute | ||
| + | <!--T:33--> | ||
*Rich Klinghoffer, Presage Biosciences | *Rich Klinghoffer, Presage Biosciences | ||
| + | <!--T:34--> | ||
*Krishna Kota and Rajini Mudhasani, United States Army Medical Research Institute for Infectious Diseases | *Krishna Kota and Rajini Mudhasani, United States Army Medical Research Institute for Infectious Diseases | ||
| + | <!--T:35--> | ||
*Nir London, Weizmann Institute | *Nir London, Weizmann Institute | ||
| + | <!--T:36--> | ||
*Ji Luo, National Cancer Institute | *Ji Luo, National Cancer Institute | ||
| + | <!--T:37--> | ||
*Carla Mattos, Northeastern University | *Carla Mattos, Northeastern University | ||
| + | <!--T:38--> | ||
*Lynn McGregor, University of California - San Francisco | *Lynn McGregor, University of California - San Francisco | ||
| + | <!--T:39--> | ||
*Campbell McInnes, PPI Pharmaceuticals | *Campbell McInnes, PPI Pharmaceuticals | ||
| + | <!--T:40--> | ||
*Debbie Morrison, National Cancer Institute | *Debbie Morrison, National Cancer Institute | ||
| + | <!--T:41--> | ||
*Bjoern Papke, The University of North Carolina at Chapel Hill | *Bjoern Papke, The University of North Carolina at Chapel Hill | ||
| + | <!--T:42--> | ||
*Arvind Ramanthan, Oak Ridge National Lab | *Arvind Ramanthan, Oak Ridge National Lab | ||
| + | <!--T:43--> | ||
*Adam Renslo, University of California - San Francisco | *Adam Renslo, University of California - San Francisco | ||
| + | <!--T:44--> | ||
*Robert Rottapel, University of Toronto | *Robert Rottapel, University of Toronto | ||
| + | <!--T:45--> | ||
*Udo Rudloff, National Cancer Institute | *Udo Rudloff, National Cancer Institute | ||
| + | <!--T:46--> | ||
*Saori Fujita Sato, Daiichi-Sankyo | *Saori Fujita Sato, Daiichi-Sankyo | ||
| + | <!--T:47--> | ||
*Karla Satchell, Northwestern University | *Karla Satchell, Northwestern University | ||
| + | <!--T:48--> | ||
*Brian Shoichet, University of California - San Francisco | *Brian Shoichet, University of California - San Francisco | ||
| + | <!--T:49--> | ||
*Kevan Shokat, University of California - San Francisco | *Kevan Shokat, University of California - San Francisco | ||
| + | <!--T:50--> | ||
*Anton Simeonov, National Center for Advancing Translational Sciences | *Anton Simeonov, National Center for Advancing Translational Sciences | ||
| + | <!--T:51--> | ||
*Kamini Singh, Memorial Sloan Kettering Cancer Center | *Kamini Singh, Memorial Sloan Kettering Cancer Center | ||
| + | <!--T:52--> | ||
*Steve Sligar, University of Illinois | *Steve Sligar, University of Illinois | ||
| + | <!--T:53--> | ||
*Chris Stanley, Oak Ridge National Laboratory | *Chris Stanley, Oak Ridge National Laboratory | ||
| + | <!--T:54--> | ||
*Fred Streitz, Lawrence Livermore National Lab | *Fred Streitz, Lawrence Livermore National Lab | ||
| + | <!--T:55--> | ||
*Rick Stevens, Argonne National Lab | *Rick Stevens, Argonne National Lab | ||
| + | <!--T:56--> | ||
*Sriram Subramaniam, National Cancer Institute | *Sriram Subramaniam, National Cancer Institute | ||
| + | <!--T:57--> | ||
*Marco Tonelli, Nuclear Magnetic Resonance Facility at Madison, Wisconsin | *Marco Tonelli, Nuclear Magnetic Resonance Facility at Madison, Wisconsin | ||
| + | <!--T:58--> | ||
*David Webber, University of Maryland | *David Webber, University of Maryland | ||
| + | <!--T:59--> | ||
*Jim Wells, University of California - San Francisco | *Jim Wells, University of California - San Francisco | ||
| + | <!--T:60--> | ||
*Ken Westover, University of Texas - Southwestern | *Ken Westover, University of Texas - Southwestern | ||
| + | <!--T:61--> | ||
*Fred Wittinghofer, Max Planck Institute | *Fred Wittinghofer, Max Planck Institute | ||
| + | <!--T:62--> | ||
*Kris Wood, Duke University | *Kris Wood, Duke University | ||
| + | <!--T:63--> | ||
*Tina Yuan, Broad Institute | *Tina Yuan, Broad Institute | ||
| + | </translate> | ||
Latest revision as of 21:47, 29 October 2019
Contents
RAS Collaborations
Community Collaborations
The combined expertise of RAS Initiative researchers and the following outside organizations have expanded research capabilities and resulted in synergistic efforts to drive discoveries.
Pancreatic Cancer Action Network
Of all the cancers, pancreatic cancer is the one most often driven by mutations in RAS genes. The Pancreatic Cancer Action NetworkExit Disclaimer (PanCan) advocates for patients and raises funds for research. PanCan has coordinated with the RAS Initiative to fund postdoctoral awards and fellowships that complement the Initiative's work at the Frederick National Laboratory.
DARPA Big Mechanism Program
The Defense Advanced Research Projects Agency (DARPA) has established the Big MechanismExit Disclaimer program to use machine learning to read abstracts and papers from the scientific literature to develop causal, explanatory relationships. The RAS Initiative is cooperating with the Big Mechanism Program to try to understand and reveal new ways to look at the RAS signaling network.
Department of Energy Pilot Program
The Department of Energy (DOE) maintains vast computational power as part of its own national missions. The DOE’s Molecular Level Pilot Program and the RAS Initiative are cooperating to apply the DOE’s unique capabilities to better model and understand how individual RAS molecules behave at the membrane in living cells.
Technical Collaborations
Decades of effort by thousands of researchers around the world have resulted in numerous specialized tools and areas of knowledge that can be applied to better understand how cancers work. Scientists in the RAS Initiative have established cooperative relationships with outside experts to access the capabilities that are most important to attack mutant RAS.
- Mariano Barbacid, Spanish National Cancer Research Center
- Cyril Benes, Massachusetts General Hospital
- Marco Biancucci, Northwestern University - Chicago
- Larry Botticelli, Pharma Arava, LLC
- Arul Chinnaiyan, University of Michigan
- Geoffrey Clark, University of Louisville
- Channing Der, University of North Carolina
- Martin Drysdale, Beatson Institute
- Walter Englaro, Sanofi-Aventis
- Sandra Gabelli, Johns Hopkins
- Angel Garcia, Los Alamos National Lab
- William Garland, Tosk, Inc.
- Rodolfo Ghirlando, NIDDK
- Michael Gross, Washington University
- Jay Groves, University of California - Berkeley
- Frank Heinrich, National Institute for Standards and Technology
- Paul Henderson, University of California - Davis
- John Hunter, University of Texas - Southwestern
- Esmaiel Jabbari, University of South Carolina
- Hans Robert Kalbitzer, University of Regensburg - Germany
- Perry Kennedy, H. Lee Moffitt Cancer Center & Research Institute
- Rich Klinghoffer, Presage Biosciences
- Krishna Kota and Rajini Mudhasani, United States Army Medical Research Institute for Infectious Diseases
- Nir London, Weizmann Institute
- Ji Luo, National Cancer Institute
- Carla Mattos, Northeastern University
- Lynn McGregor, University of California - San Francisco
- Campbell McInnes, PPI Pharmaceuticals
- Debbie Morrison, National Cancer Institute
- Bjoern Papke, The University of North Carolina at Chapel Hill
- Arvind Ramanthan, Oak Ridge National Lab
- Adam Renslo, University of California - San Francisco
- Robert Rottapel, University of Toronto
- Udo Rudloff, National Cancer Institute
- Saori Fujita Sato, Daiichi-Sankyo
- Karla Satchell, Northwestern University
- Brian Shoichet, University of California - San Francisco
- Kevan Shokat, University of California - San Francisco
- Anton Simeonov, National Center for Advancing Translational Sciences
- Kamini Singh, Memorial Sloan Kettering Cancer Center
- Steve Sligar, University of Illinois
- Chris Stanley, Oak Ridge National Laboratory
- Fred Streitz, Lawrence Livermore National Lab
- Rick Stevens, Argonne National Lab
- Sriram Subramaniam, National Cancer Institute
- Marco Tonelli, Nuclear Magnetic Resonance Facility at Madison, Wisconsin
- David Webber, University of Maryland
- Jim Wells, University of California - San Francisco
- Ken Westover, University of Texas - Southwestern
- Fred Wittinghofer, Max Planck Institute
- Kris Wood, Duke University
- Tina Yuan, Broad Institute
